NCT02544607

Ketamine for Depression: An MRI Study

Baseline Insular Dysfunction as a Predictor of Ketamine's Antidepressant Effects in Anxious Depression

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 25 (actual)
• Sponsor: Massachusetts General Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 64 Years
• Healthy volunteers: Accepted

Summary

Ketamine has been shown to decrease symptoms of anxious depression quickly. This decrease has been shown to last for up to one month. MRI technology will be used before and after ketamine for patients with depression to examine the extent to which certain brain areas predict ketamine's antidepressant effects.

Detailed description

Ketamine's antidepressant effects were measured with Hamilton Depression Rating Scale (HDRS). MRI data will also be analyzed to examine the extent to which certain brain areas predict ketamine's antidepressant effects.

Conditions

• Depression
• Anxious Depression
• Major Depressive Disorder

Interventions

Type	Name	Description
DRUG	Ketamine	Ketamine 0.5mg/kg over 40 minutes IV
OTHER	Magnetic Resonance Imaging (MRI)	MRI technology will be used before and after ketamine for patients with depression

Timeline

• Start date: 2016-03-01
• Primary completion: 2017-12-29
• Completion: 2017-12-29
• First posted: 2015-09-09
• Last updated: 2019-04-16
• Results posted: 2019-04-04

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study